The COVID-19 crisis has been a real boon () to Pfizer. Not only has it doubled Pfizer’s annual revenue, but it has also given the drugmaker unique weight in determining U.S. health policy—something that concerns even staunch vaccine-pushers like Dr. Paul Offit.
Pfizer’s revenue in 2021 was $81.3 billion—approximately double that of 2020—and its COVID-19 vaccine accounted for $36.78 billion of that, which dominates 70% of the U.S. and European markets. Meanwhile Paxlovid, its COVID-19 drug, has become a standard treatment choice in hospitals. This despite findings showing the shot doesn’t prevent infection or transmission, and causes COVID rebound.
The U.S. had thrown away 82.2 million expired COVID-19 vaccine doses as of mid-May, yet the Biden administration ordered another 105 million doses at the end of June for a fall booster campaign that will cost taxpayers $3.2 billion.
Pfizer’s contracts are almost exclusively slanted in Pfizer’s favor. They’re guaranteed payment while having no financial liability for injuries and deaths, and it appears this applies even if they were to be found guilty of fraud.
